Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2007

MedImmune Leases New Facility to Enhance Flu Vaccine Program

  • MedImmune will use a portion of the Human Genome Sciences headquarters facility located in Rockville, MD, to develop and manufacture clinical trial material for cell culture-based seasonal and pandemic influenza vaccine.

    “While we are currently expanding our biologics manufacturing facility in Frederick, MD, for potential use in producing pandemic vaccine as well as other products in our pipeline, the immediate availability of the existing Human Genome Sciences facility allows us to expedite certain development steps toward expanding our capacity to produce cell culture-based influenza vaccines,” explains Alan Taggart, vp of government project management.

    “This should be particularly useful as we prepare to initiate our clinical trials of cell culture influenza vaccine under our HHS contract commitment.” The award is for five years, totalling approximately $170 million.

    MedImmune currently develops, manufactures, and markets FluMist®, a live, attenuated, needle-free seasonal influenza vaccine. The company is also working with the NIAID to apply its technology to develop pandemic influenza vaccines.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »